Florida / New York / No Carolina
Ph: 561.316.3330

Mark Eisner MD, M.P.H. Appointed Chief Medical Officer at Vir Biotechnology

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Summation

  • Eisner has also been with Genentech nearly 11 years and served as their Senior Vice President of Global Head of Product Development Immunology, Infectious Disease and Ophthalmology and was accountable for late-stage clinical development of many products including strategy, clinical trials and budget.

Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Mark D. Eisner, M.D., M.P.H. will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 03, 2024. Dr. Eisner will be a part of the company’s Executive Management Team and will report directly to Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer.

Mark Eisner MD comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In this role, he led all development functions which included biometrics, regulatory, clinical science, clinical operations, drug safety, and pharmacology. Prior to his most recent tenure with Sonoma Biotherapeutics, Dr. Eisner served as CMO at FibroGen where he led all development functions, which included being the Head of China clinical development and clinical operations. Dr. Eisner has also been with Genentech nearly 11 years and served as their Senior Vice President of Global Head of Product Development Immunology, Infectious Disease and Ophthalmology and was accountable for late-stage clinical development of many products including strategy, clinical trials and budget. He brings to Vir deep immunology and infectious disease expertise with clinical development experience. Dr. Eisner has an impressive track record of leading teams during times of strategically evolving portfolios.

“We are delighted to welcome Mark, a seasoned and highly respected scientist, clinician, and leader, to Vir’s Executive Management Team. His exceptional leadership skills with late-stage clinical experience and deep knowledge of immunology and infectious disease will be critical to the next phase of Vir’s growth,” said Dr. De Backer. “In addition to his proven track record of overseeing multiple products across various indications while securing breakthrough therapy designation, Mark’s visionary and enterprise mindset will be of great benefit to Vir as we focus on bringing medicine to patients with unmet medical needs.”

Dr. Eisner completed his A.B. degree in human biology at Stanford University and his M.D. degree at the University of Pennsylvania School of Medicine. He also has an M.P.H. focusing on epidemiology from the University of California Berkeley, School of Public Health. He has an impressive list of publications and patents, honors and awards, and services for professional organizations.

“I am thrilled to be joining Vir at this critical time and am looking forward to working with the talented teams to advance our clinical development programs,” said Dr. Eisner. “I have always admired the bold mission of the company. Patients have always been my guiding compass, so I am excited to have this opportunity to help translate Vir’s groundbreaking science into advances for human health.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Ronil Patel Appointed Chief Business Officer at RevOpsis Therapeutics

Ronil Patel currently serves as a strategic advisor to Collage Venture Partners and was previously the Chief Business Officer at Ocuphire Pharma, a publicly traded ophthalmology biotechnology company. Prior to Ocuphire, Patel led business development for Point Guard Partners and Oculos Clinical Research (now iuvo Bioscience). Patel has been instrumental in biotech research and development and global business expansion. He has also contributed to teams that have secured approximately $100 million in funding and finalized licensing and exit deals valued at over $500 million.

Julie Sawyer Montgomery | Appointed Executive Vice President for Diagnostics at Danaher Corporation

Julie Sawyer Montgomery currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to the President and Chief Executive Officer, Rainer Blair.

Franck Mevellec Appointed Senior Director, Business Development at Asymchem

Franck Mevellec boasts a proven track record of success, having held key positions at industry leaders like Bayer Healthcare (R&D), Teva Pharmaceuticals (portfolio director), Minakem (BD director), and most recently, Seqens (global head of sales). He joins Asymchem with a focus on expanding the company’s footprint across Europe.

By using this website you agree to accept Medical Device News Magazine Privacy Policy